Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - PROGENICS PHARMACEUTICALS INC | form10_q09302015.htm |
| EX-32 - EXHIBIT 32 CERTIFICATION - PROGENICS PHARMACEUTICALS INC | ex3209302015.htm |
| EX-31.1 - EXHIBIT 31.1 CERTIFICATION - PROGENICS PHARMACEUTICALS INC | ex31_109302015.htm |
| EX-31.2 - EXHIBIT 31.2 CERTIFICATION - PROGENICS PHARMACEUTICALS INC | ex31_209302015.htm |
Progenics Pharmaceuticals, Inc.
Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends
(in thousands)
|
|
Nine Months
Ended September 30, |
Years Ended December 31,
|
||||||||||||||||||||||
|
|
2015
|
2014
|
2013
|
2012
|
2011
|
2010
|
||||||||||||||||||
|
Determination of earnings (loss):
|
||||||||||||||||||||||||
|
Income (loss) from operations
|
$
|
(31,965
|
)
|
$
|
4,410
|
|
$
|
(42,934
|
)
|
$
|
(35,431
|
) |
$
|
10,381
|
|
$
|
(69,820
|
)
|
||||||
|
Add:
|
||||||||||||||||||||||||
|
Fixed charges
|
271
|
373
|
710
|
410
|
695
|
709
|
||||||||||||||||||
|
|
||||||||||||||||||||||||
|
Earnings (loss), as adjusted
|
$ |
(31,694
|
)
|
$
|
4,783
|
|
$
|
(42,224
|
)
|
$
|
(35,021
|
) |
$
|
11,076
|
|
$
|
(69,111
|
)
|
||||||
|
|
||||||||||||||||||||||||
|
Fixed charges:
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||
|
Estimate of interest within rental expense
|
271
|
373
|
710
|
410
|
695
|
709
|
||||||||||||||||||
|
|
||||||||||||||||||||||||
|
Fixed charges
|
$
|
271
|
$
|
373
|
$
|
710
|
$
|
410
|
$
|
695
|
$
|
709
|
||||||||||||
|
|
||||||||||||||||||||||||
|
Preferred stock dividends
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
-
|
||||||||||||
|
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||
|
Ratio of earnings (loss) to fixed charges and preferred stock dividends
|
*
|
13
|
*
|
*
|
16
|
*
|
||||||||||||||||||
|
Coverage deficiency amount for total fixed charges and preferred stock dividends (1)
|
$
|
31,965
|
$
|
-
|
$
|
42,934
|
$
|
35,431
|
$
|
-
|
$
|
69,820
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
For the years ended 2010, 2012, 2013 and for the nine months ended September 30, 2015, the Company's coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.
|
|
||||||||||||||||||